Category: Synthes Inc.
A federal judge rules that former Synthes sales rep John Marotta broke a non-compete agreement when he helped form and lead Emerge Medical.
A slate of medical device makers, including Becton Dickinson, Johnson & Johnson and Zoll, land federal contracts collectively worth nearly $370 million.
Federal agencies have handed out a slew of contracts and contract extensions in recent weeks, including about $370 million in deals for medical supplies and devices.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
FDA's official blog brought to you from FDA's senior leadership and staff stationed at home and abroad - sharing news, background, announcements and other information about the work done at the FDA on behalf of the American public.
By: John Roth
In my last post, I explained how FDA's Office of Criminal Investigation (OCI) works when a small portion of the industry fails to adequately respond to regulatory action. For Abbott Laboratories and Amgen, the price for regulatory malfeasance was high: $1.4 billion – yes, billion – paid in criminal and civil penalties to the United States.
Johnson & Johnson's Synthes subsidiary warns of the risk that 1 of its soft tissue retractors might fragment during use.
Hong Kong's Medical Device Control Office said Johnson & Johnson's (NYSE:JNJ) Synthes division issued a warning about the risk of injury from 1 of its soft tissue retractors.
Wall Street analysts worry that there may be larger negative trends for the industry as Johnson & Johnson reports declines in some of its medical device businesses.
Healthcare titan Johnson & Johnson (NYSE:JNJ) scored some hits and misses with Wall Street upon releasing its 1st-quarter 2013 earnings report, touting a 10% overall increase in medical devices and diagnostics revenues but failing to thrill analysts.
A comparison of asset values and share values for medical device companies from the MassDevice Big 100 database.
One way to assess stock values is to compare the stock's share price with its asset value.
The latter is the number of shares outstanding divided into total assets. When the result is compared with share prices, it can help investors decide whether a stock is over- or under-valued.
We took a look at the asset values for 15 of the world's largest pure-play medical device companies and then compared them with the companies' stock price.
, Boston Scientific
, Dentsply International Inc.
, Edwards Lifesciences
, Essilor International
, Intuitive Surgical Inc.
, Mindray Medical International Ltd.
, ResMed Inc.
, Smith & Nephew
, St. Jude Medical
, Stryker Corp.
, Synthes Inc.
, Varian Medical Systems